Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

80.93 -1.46 (-1.77%)
Official Closing Price Updated: 5:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Merck & Co

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
24 25 Next >
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Regardless of PD-L1 Expression
From Merck & Co., Inc.
Via Business Wire
Merck and AstraZeneca Present Final Results of Key Secondary Overall Survival Endpoint From Phase 3 PROpel Trial at 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium
From Merck & Co., Inc.
Via Business Wire
MarketBeat Week in Review – 2/6 - 2/10
Markets are closed the week looking for direction as investors believe a soft landing is not possible and higher interest rates are likely 
Via MarketBeat
Topics Artificial Intelligence Economy
Should Investors Buy or Sell the Vaccinex Patent News?
Shares of Vaccinex, Inc. are higher on February 7 on news that the clinical-stage biotechnology company secured a patent. Is it time to buy or sell the news? 
Via MarketBeat
Topics Intellectual Property
Is Merck Stock a Buy After Its Post-Earnings Sell-Off?
Despite beating analysts’ expectations on the top and bottom lines, MRK stock fell after earnings. This article analyzes if investors should jump in 
Via MarketBeat
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma
From Merck & Co., Inc.
Via Business Wire
Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
From Merck & Co., Inc.
Via Business Wire
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a 
Via MarketBeat
FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
From Merck & Co., Inc.
Via Business Wire
Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO (fluralaner) Chews for Dogs
From Merck & Co., Inc.
Via Business Wire
Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Enzalutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer to Stop for Futility
From Merck & Co., Inc.
Via Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy in First-Line Advanced or Unresectable Biliary Tract Cancer in KEYNOTE-966 Trial
From Merck & Co., Inc.
Via Business Wire
Is the Pain Over for Baudax Bio Investors after a 70% Spike?
Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000. 
Via MarketBeat
Merck Announces Second-Quarter 2023 Dividend
From Merck & Co., Inc.
Via Business Wire
Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.
From Merck & Co., Inc.
Via Business Wire
Merck Named One of America’s Most JUST Companies by JUST Capital and CNBC, Industry Leader in Pharmaceuticals and Biotech
From Merck & Co., Inc.
Via Business Wire
Merck to Hold Fourth-Quarter and Full-Year 2022 Sales and Earnings Conference Call February 2
From Merck & Co., Inc.
Via Business Wire
Merck to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Big Health Care Stocks to Watch in the New Year
Here are three health care stocks to watch as the New Year begins. Two have a moderate Buy rating while one is a Hold, for now. 
Via MarketBeat
Merck to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
From Merck & Co., Inc.
Via Business Wire
Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer
From Merck & Co., Inc.
Via Business Wire
LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
From Seagen Inc.
Via Business Wire
AstraZeneca and Merck Provide Update on US Regulatory Review of LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone as Treatment of Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
Via ACCESSWIRE
Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.
From Merck & Co., Inc.
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Apollo Endosurgery, Inc. (Nasdaq - APEN), Imago BioSciences, Inc. (Nasdaq - IMGO), Opiant Pharmaceuticals Inc. (Nasdaq - OPNT), Benefitfocus, Inc. (Nasdaq - BNFT)
From Brodsky & Smith LLC
Via GlobeNewswire
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope
EQNX::TICKER_START (OTCQB:BVAXF),(NASDAQ:CTIC),(NASDAQ:SGEN),(NYSE:MRK),(NASDAQ:IMGN) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Intellectual Property
Merck to Present Data From Its Hematology Portfolio and Promising Pipeline at the 64th American Society of Hematology (ASH) Annual Meeting
From Merck & Co., Inc.
Via Business Wire
Merck Announces First-Quarter 2023 Dividend
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
24 25 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.